BridgeMD
New treatment option for Colorectal Cancer
Official title Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer
ClinicalTrials.gov ID: NCT05202314
What this study is testing
What is Immunotherapy (Camrelizumab)?
Immunotherapy (Camrelizumab) is an investigational medicine, being studied as a potential treatment for colorectal cancer.
Also referred to as Chemotheray (CAPOX or mFOLFOX6).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patients with obstruction are associated with worse oncologic outcomes compared with those having nonobstructive tumors. Conventionally, patients with malignant large bowel obstruction receive emergency surgery, with morbidity rates of 30%-60% and mortality rates of 7-22%, and about two-thirds of such patients end up with a permanent stoma.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma
- Able to give written, informed consent
- Primary tumor was resectable
- ECOG score 0 or 1
- Haemoglobin greater than 100 g/L after transfusion before chemotherapy,
You likely can't join if
- Distal rectal cancers(equal or less than 10cm from the anal verge)
- Patients with signs of peritonitis and/or bowel perforation
- Patients who did not give informed consent
- Patients who were considered unfit for operative treatment or refuse surgery.
- Patients with suspected or proven metastatic adenocarcinoma;
- Patients with unresectable colorectal cancer, or planning for palliative treatment.
See the full eligibility criteria
- Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma
- Able to give written, informed consent
- Primary tumor was resectable
- ECOG score 0 or 1
- Haemoglobin greater than 100 g/L after transfusion before chemotherapy,
- White blood cells greater than 3.0×10# /L
- Platelets greater than 100×10# / L;
- Glomerular filtration rate greater than 50 mL per minute as calculated by the Wright or Cockroft formula
- Bilirubin less than 1.5×Upper Limit of Normal(ULN)
- ALT and AST less than 2.5×ULN
- Distal rectal cancers(equal or less than 10cm from the anal verge)
- Patients with signs of peritonitis and/or bowel perforation
- Patients who did not give informed consent
- Patients who were considered unfit for operative treatment or refuse surgery.
- Patients with suspected or proven metastatic adenocarcinoma;
- Patients with unresectable colorectal cancer, or planning for palliative treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.